Ontario Construction News staff writer
Roche Canada will invest $500 million over five years to build a Global Pharma Technical Operations site to oversee its global supply chain in Mississauga. This investment is expected to enhance Ontario’s competitiveness and leadership in the life sciences sector.
“We are leaders in the creation of life-saving medicines, treatments, and medical equipment,” said Premier Doug Ford.
“Roche’s new operation hub in Mississauga will further anchor Ontario’s position as a titan in life sciences, creating good-paying jobs in the community, and ensuring Ontario’s best and brightest minds advance the important work Roche does to transform health care here in our province and beyond.”
The Global Pharma Technical Operations site will support Hoffmann-La Roche Limited’s global manufacturing and supply chain operations, including monitoring safety, quality and distribution of pharmaceutical products shipped around the world.
In 2012, Roche established Mississauga as a product development site, overseeing clinical trials in Canada and globally. The success of this site, along with Ontario’s highly skilled science, technology, engineering and mathematics (STEM) workforce, world-class colleges and universities and competitive business environment, saw the province win out over 12 international locations and Roche sites to secure this new investment, while positioning the province for future opportunities.
“Ontario is home to leading-edge research institutions, we have a top tier STEM workforce, and our life science and innovation sectors are amongst the best in the world,” said Minister Vic Fedeli, minister of economic development, job creation and trade.
“We are proud that Roche has expressed confidence in our province and selected Ontario as the home for their new site. This will mean 500 new well-paying jobs and will further bolster Ontario’s competitiveness in the life sciences sector.”
The human health life sciences sector generates more than $53.2 billion annually in revenue. The government is working with life sciences partners to further unlock the potential of the sector through the development of a Life Sciences Strategy to harness initiatives and commitments, including health care procurement reform and data modernization.
“This significant investment in Ontario by Roche will help build and strengthen our province as a whole,” said Christine Elliott, health minister. “Today’s announcement is good news for Ontarians as we work towards economic recovery and demonstrates opportunities to work together and find innovative ways to strengthen our health care system.”
The announcement was made by Premier Doug Ford, Christine Elliott, Deputy Premier and Minister of Health, Vic Fedeli, Minister of Economic Development, Job Creation and Trade, and Ronnie Miller, President and CEO of Roche Pharmaceuticals, Canada.
Ronnie Miller, president and CEO at Roche Pharmaceuticals says Ontario was chosen for the site based on a strong competitive business environment and experienced workforce.
Roche is the world’s largest biotech company and a world leader in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Founded in 1931, Roche Canada employs more than 1,800 people across the country through its Pharmaceuticals division in Mississauga, Ontario, and Diagnostics as well as Diabetes Care divisions in Laval, Quebec.
In 2018, Ontario’s life sciences sector exported about $9.7 billion in goods, representing 65 per cent of total Canadian life sciences exports. Ontario has approximately 1,900 life sciences firms ― 44 per cent of Canada’s total.